KR20040003031A - 무쾌감증 치료용 약물의 제조를 위한 알카노일ｌ-카르니틴의 용도 - Google Patents
무쾌감증 치료용 약물의 제조를 위한 알카노일ｌ-카르니틴의 용도 Download PDFInfo
- Publication number
- KR20040003031A KR20040003031A KR10-2003-7015576A KR20037015576A KR20040003031A KR 20040003031 A KR20040003031 A KR 20040003031A KR 20037015576 A KR20037015576 A KR 20037015576A KR 20040003031 A KR20040003031 A KR 20040003031A
- Authority
- KR
- South Korea
- Prior art keywords
- carnitine
- stress
- acetyl
- rats
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 alkanoyl l-carnitine Chemical compound 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title claims description 7
- 208000007415 Anhedonia Diseases 0.000 title 1
- 229960001518 levocarnitine Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 10
- 230000037005 anaesthesia Effects 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical group CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 69
- 239000002253 acid Substances 0.000 claims description 20
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 6
- 229940095064 tartrate Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- MUZDLCBWNVUYIR-UHFFFAOYSA-L magnesium;2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)C(O)C(O)C([O-])=O MUZDLCBWNVUYIR-UHFFFAOYSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 230000035882 stress Effects 0.000 description 74
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 70
- 241000700159 Rattus Species 0.000 description 58
- 230000037326 chronic stress Effects 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 37
- 229960003638 dopamine Drugs 0.000 description 35
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 32
- 229960004801 imipramine Drugs 0.000 description 32
- 230000000694 effects Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 238000012549 training Methods 0.000 description 21
- 235000009499 Vanilla fragrans Nutrition 0.000 description 20
- 244000263375 Vanilla tahitensis Species 0.000 description 20
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 20
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 16
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 15
- 229960002464 fluoxetine Drugs 0.000 description 15
- 235000012054 meals Nutrition 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 229960003920 cocaine Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- GJTJQSPLLQWKMB-SECBINFHSA-N (3R)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentanoate Chemical group C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O GJTJQSPLLQWKMB-SECBINFHSA-N 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LRCNOZRCYBNMEP-SECBINFHSA-N O-isobutyryl-L-carnitine Chemical compound CC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LRCNOZRCYBNMEP-SECBINFHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000292A ITRM20010292A1 (it) | 2001-05-29 | 2001-05-29 | Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia. |
| ITRM2001A000292 | 2001-05-29 | ||
| IT2001RM000319A ITRM20010319A1 (it) | 2001-06-08 | 2001-06-08 | Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia. |
| ITRM2001A000319 | 2001-06-08 | ||
| PCT/IT2002/000339 WO2002096411A1 (en) | 2001-05-29 | 2002-05-24 | Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040003031A true KR20040003031A (ko) | 2004-01-07 |
Family
ID=26332845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7015576A Ceased KR20040003031A (ko) | 2001-05-29 | 2002-05-24 | 무쾌감증 치료용 약물의 제조를 위한 알카노일ｌ-카르니틴의 용도 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040171685A1 (enExample) |
| EP (1) | EP1399143B1 (enExample) |
| JP (1) | JP2004532867A (enExample) |
| KR (1) | KR20040003031A (enExample) |
| AT (1) | ATE345124T1 (enExample) |
| CA (1) | CA2448246A1 (enExample) |
| CZ (1) | CZ20033222A3 (enExample) |
| DE (1) | DE60216090T2 (enExample) |
| DK (1) | DK1399143T3 (enExample) |
| ES (1) | ES2275881T3 (enExample) |
| HU (1) | HUP0400007A2 (enExample) |
| MX (1) | MXPA03010920A (enExample) |
| PL (1) | PL367628A1 (enExample) |
| PT (1) | PT1399143E (enExample) |
| SK (1) | SK15862003A3 (enExample) |
| WO (1) | WO2002096411A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20020620A1 (it) * | 2002-12-13 | 2004-06-14 | Sigma Tau Ind Farmaceuti | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
| WO2023084531A1 (en) * | 2021-11-12 | 2023-05-19 | Celagenex Research (India) Pvt. Ltd. | A synergistic composition for activating intracellular secondary messenger(camp) pathway |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| IT1291930B1 (it) * | 1997-06-18 | 1999-01-21 | Sigma Tau Ind Farmaceuti | Composizione riequilibratrice delle turbe dell'umore in individui sani |
-
2002
- 2002-05-24 ES ES02741156T patent/ES2275881T3/es not_active Expired - Lifetime
- 2002-05-24 DE DE60216090T patent/DE60216090T2/de not_active Expired - Fee Related
- 2002-05-24 DK DK02741156T patent/DK1399143T3/da active
- 2002-05-24 PT PT02741156T patent/PT1399143E/pt unknown
- 2002-05-24 WO PCT/IT2002/000339 patent/WO2002096411A1/en not_active Ceased
- 2002-05-24 HU HU0400007A patent/HUP0400007A2/hu unknown
- 2002-05-24 CA CA002448246A patent/CA2448246A1/en not_active Abandoned
- 2002-05-24 US US10/478,998 patent/US20040171685A1/en not_active Abandoned
- 2002-05-24 AT AT02741156T patent/ATE345124T1/de not_active IP Right Cessation
- 2002-05-24 KR KR10-2003-7015576A patent/KR20040003031A/ko not_active Ceased
- 2002-05-24 CZ CZ20033222A patent/CZ20033222A3/cs unknown
- 2002-05-24 JP JP2002592921A patent/JP2004532867A/ja active Pending
- 2002-05-24 PL PL02367628A patent/PL367628A1/xx unknown
- 2002-05-24 MX MXPA03010920A patent/MXPA03010920A/es active IP Right Grant
- 2002-05-24 SK SK1586-2003A patent/SK15862003A3/sk unknown
- 2002-05-24 EP EP02741156A patent/EP1399143B1/en not_active Expired - Lifetime
-
2005
- 2005-12-20 US US11/311,406 patent/US20060148896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010920A (es) | 2004-02-27 |
| ATE345124T1 (de) | 2006-12-15 |
| PL367628A1 (en) | 2005-03-07 |
| US20040171685A1 (en) | 2004-09-02 |
| SK15862003A3 (sk) | 2004-06-08 |
| HUP0400007A2 (hu) | 2004-04-28 |
| DE60216090D1 (de) | 2006-12-28 |
| DE60216090T2 (de) | 2007-05-31 |
| DK1399143T3 (da) | 2007-03-26 |
| EP1399143B1 (en) | 2006-11-15 |
| CZ20033222A3 (cs) | 2004-06-16 |
| CA2448246A1 (en) | 2002-12-05 |
| EP1399143A1 (en) | 2004-03-24 |
| WO2002096411A1 (en) | 2002-12-05 |
| ES2275881T3 (es) | 2007-06-16 |
| US20060148896A1 (en) | 2006-07-06 |
| JP2004532867A (ja) | 2004-10-28 |
| PT1399143E (pt) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6335361B1 (en) | Method of treating benign forgetfulness | |
| EP3320895B1 (en) | Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine | |
| EP3684350A1 (en) | Amino acids compositions for the treatment of neuronal injury | |
| KR102439451B1 (ko) | 뇌 활성 증진용 조성물 | |
| US20250367206A1 (en) | 1-methylxanthine-based bioactive composition and method of use thereof | |
| KR20210023847A (ko) | 쓴맛 아미노산을 포함하는, 요법 및 건강관리용 조성물 | |
| KR20240057401A (ko) | 파라잔틴-기반 카페인 대용 조성물 및 느린 카페인 대사자에서의 이의 사용 방법 | |
| KR102722498B1 (ko) | 인지 기능 개선용 조성물 및 불안양 증상 개선용 조성물, 및 뇌 위축 억제용 조성물 | |
| KR20040084168A (ko) | 피니톨 또는 카이로이노시톨을 포함하는 간 질환 예방 및치료용 조성물 | |
| DE60020833T2 (de) | Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag | |
| JP6677775B2 (ja) | 筋肉増強剤 | |
| KR101899546B1 (ko) | 플로로글루시놀을 유효성분으로 하는 수면 장애 개선, 예방 또는 치료용 조성물, 또는 gaba a 수용체 효능제의 내성 억제 또는 부작용 경감용 조성물 | |
| US20080161604A1 (en) | Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy | |
| JP7655224B2 (ja) | 筋質向上剤 | |
| EP1399143B1 (en) | Use of acetyl l-carnitine for the preparation of a medication to treat anhedonia | |
| US8952059B2 (en) | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| US20020077349A1 (en) | Method of treating age-related vision impairment | |
| US20240091185A1 (en) | Composition for improving cognitive function, agent for improving cognitive function, and food for improving cognitive function | |
| US8013016B2 (en) | Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome | |
| WO2023203210A1 (de) | Nahrungsmittel-zubereitung zur verwendung zum verzehr durch personen mit einer nahrungsmittel-unverträglichkeit gegenüber gamma-aminobuttersäure (gaba) | |
| EP0344158A1 (de) | Schmerzpräparat. | |
| JP2008169144A (ja) | 心的外傷後ストレス障害予防剤、治療剤及び飲食物 | |
| Directo | The Effects Of A Proprietary Multi-Ingredient Ergogenic Supplement On Body Composition During High-Volume Periodized Resistance Training |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031128 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20070417 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080325 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20080619 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20080325 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |